Pentixapharm AG

Pentixapharm's CXCR4-Targeted Radiopharmaceuticals Show Promise in Primary Aldosteronism and Bladder Cancer

- Pentixapharm presented extensive clinical data at EANM 2025 demonstrating [⁶⁸Ga]Ga-PentixaFor's potential to improve diagnosis in Primary Aldosteronism, a frequently underdiagnosed cause of secondary hypertension. - The diagnostic candidate showed high potential to significantly improve patient subtyping compared to adrenal venous sampling, the current invasive gold standard for Primary Aldosteronism. - First-in-human data for therapeutic candidate [¹⁷⁷Lu]Lu-PentixaTher in bladder cancer patients demonstrated initial signs of therapeutic activity, further validating CXCR4 as a clinically relevant target. - The findings showcase the versatility of Pentixapharm's CXCR4-targeted platform across cardiovascular, endocrine, and oncologic diseases.